Earnings Call · Q3 FY2021·2021-11-01

Q3 21EPS +30.16%·Rev n/aQ2 21EPS +20.78%·Rev n/aQ1 21EPS -14.29%·Rev n/aQ4 20EPS -27.42%·Rev n/a⚠ consensus missing

Kiniksa Pharmaceuticals International, plc KNSA

Rachel Frank — Head of Investor Relations

Sanj Patel — Chief Executive Officer

Ross Moat — Chief Commercial Officer

Eben Tessari — Chief Medical Officer

Mark Ragosa — Chief Financial Officer

+22.5%1d on move date+22.3% vs SPY3d+44.9%5d+41.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more KNSA calls or request research access.

More KNSA calls Browse calls Request research access